Cargando…

Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease

BACKGROUND: Chronic graft‐versus‐host disease (GVHD) is a potentially life‐threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) treatment for hematologic malignancies. There are limited patient‐reported data concerning symptom burden and effects on activities of dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jingbo, Hamilton, Betty K., Turnbull, James, Stewart, Susan K., Vernaya, Alla, Bhatt, Valkal, Meyers, Oren, Galvin, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939096/
https://www.ncbi.nlm.nih.gov/pubmed/36394207
http://dx.doi.org/10.1002/cam4.5209
_version_ 1784890769917607936
author Yu, Jingbo
Hamilton, Betty K.
Turnbull, James
Stewart, Susan K.
Vernaya, Alla
Bhatt, Valkal
Meyers, Oren
Galvin, John
author_facet Yu, Jingbo
Hamilton, Betty K.
Turnbull, James
Stewart, Susan K.
Vernaya, Alla
Bhatt, Valkal
Meyers, Oren
Galvin, John
author_sort Yu, Jingbo
collection PubMed
description BACKGROUND: Chronic graft‐versus‐host disease (GVHD) is a potentially life‐threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) treatment for hematologic malignancies. There are limited patient‐reported data concerning symptom burden and effects on activities of daily living (ADL). METHODS: The cross‐sectional Living With Chronic GVHD Patient Survey was administered online in the United States (May–August 2020) to participants aged ≥18 years who underwent allogeneic HSCT, were diagnosed with chronic GVHD by a healthcare provider, and self‐reported active chronic GVHD (within past 5 years). Information on patient demographics, disease characteristics, symptom burden, and ability to perform ADL was collected. Symptom burden was assessed using the validated Lee Symptom Scale (range from 0–100 with higher scores indicating greater burden). All data were summarized using descriptive statistics; no formal statistical comparisons were conducted. RESULTS: Out of 580 participants who entered the survey screener, 165 participants (28.4%) across 33 states fulfilled all study eligibility criteria, completed the entire survey, and were included (age: mean [SD], 53.7 (13.8) years; median [range], 57.0 [18–78] years; female, n = 105 [63.6%]; White, n = 137 [83.0%]). Respondents described their chronic GVHD severity primarily as moderate (n = 54 [32.7%]) or severe (n = 102 [61.8%]) at the time when symptoms were at their worst. One‐third of respondents (33.9%) indicated that their chronic GVHD symptoms were at their worst for ≥1 year in duration. Mean (SD; range) Lee Symptom Scale score was 44.8 (19.4; 2–100); 44% of respondents considered “dry eye” the most burdensome symptom. Almost half of respondents (n = 73 [44.2%]) rated their overall quality of life (QoL) as poor. Participants reported a detrimental impact of symptoms on ADL, including basic activities (eg, eating, personal hygiene, dressing). CONCLUSIONS: Survey respondents self‐reported high chronic GVHD symptom burden and felt that their symptoms severely interfered with physical function and ADL. Effective strategies to mitigate chronic GVHD symptoms are needed to improve QoL among HSCT survivors.
format Online
Article
Text
id pubmed-9939096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99390962023-02-20 Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease Yu, Jingbo Hamilton, Betty K. Turnbull, James Stewart, Susan K. Vernaya, Alla Bhatt, Valkal Meyers, Oren Galvin, John Cancer Med RESEARCH ARTICLES BACKGROUND: Chronic graft‐versus‐host disease (GVHD) is a potentially life‐threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) treatment for hematologic malignancies. There are limited patient‐reported data concerning symptom burden and effects on activities of daily living (ADL). METHODS: The cross‐sectional Living With Chronic GVHD Patient Survey was administered online in the United States (May–August 2020) to participants aged ≥18 years who underwent allogeneic HSCT, were diagnosed with chronic GVHD by a healthcare provider, and self‐reported active chronic GVHD (within past 5 years). Information on patient demographics, disease characteristics, symptom burden, and ability to perform ADL was collected. Symptom burden was assessed using the validated Lee Symptom Scale (range from 0–100 with higher scores indicating greater burden). All data were summarized using descriptive statistics; no formal statistical comparisons were conducted. RESULTS: Out of 580 participants who entered the survey screener, 165 participants (28.4%) across 33 states fulfilled all study eligibility criteria, completed the entire survey, and were included (age: mean [SD], 53.7 (13.8) years; median [range], 57.0 [18–78] years; female, n = 105 [63.6%]; White, n = 137 [83.0%]). Respondents described their chronic GVHD severity primarily as moderate (n = 54 [32.7%]) or severe (n = 102 [61.8%]) at the time when symptoms were at their worst. One‐third of respondents (33.9%) indicated that their chronic GVHD symptoms were at their worst for ≥1 year in duration. Mean (SD; range) Lee Symptom Scale score was 44.8 (19.4; 2–100); 44% of respondents considered “dry eye” the most burdensome symptom. Almost half of respondents (n = 73 [44.2%]) rated their overall quality of life (QoL) as poor. Participants reported a detrimental impact of symptoms on ADL, including basic activities (eg, eating, personal hygiene, dressing). CONCLUSIONS: Survey respondents self‐reported high chronic GVHD symptom burden and felt that their symptoms severely interfered with physical function and ADL. Effective strategies to mitigate chronic GVHD symptoms are needed to improve QoL among HSCT survivors. John Wiley and Sons Inc. 2022-11-16 /pmc/articles/PMC9939096/ /pubmed/36394207 http://dx.doi.org/10.1002/cam4.5209 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Yu, Jingbo
Hamilton, Betty K.
Turnbull, James
Stewart, Susan K.
Vernaya, Alla
Bhatt, Valkal
Meyers, Oren
Galvin, John
Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
title Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
title_full Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
title_fullStr Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
title_full_unstemmed Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
title_short Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
title_sort patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939096/
https://www.ncbi.nlm.nih.gov/pubmed/36394207
http://dx.doi.org/10.1002/cam4.5209
work_keys_str_mv AT yujingbo patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT hamiltonbettyk patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT turnbulljames patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT stewartsusank patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT vernayaalla patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT bhattvalkal patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT meyersoren patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease
AT galvinjohn patientreportedsymptomburdenandimpactondailyactivitiesinchronicgraftversushostdisease